Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of chemotherapy-associated cardiotoxicity in lymphoma
2025-521205-41-00Phase 2Authorised
- Sponsor
- Aalborg University Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lymphoma comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Change in global longitudinal strain. Planned start Mar 2026; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
lymphoma
Beyond the preview
Go deeper on 2025-521205-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521205-41-00.